Overview

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Status:
Terminated
Trial end date:
2016-11-07
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim